KBC Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$255K Hold
3,945
﹤0.01% 903
2025
Q4
$265K Buy
3,945
+584
+17% +$39.3K ﹤0.01% 825
2025
Q3
$246K Hold
3,361
﹤0.01% 834
2025
Q2
$175K Sell
3,361
-2,284
-40% -$130K ﹤0.01% 920
2025
Q1
$360K Buy
5,645
+92
+2% +$5.34K ﹤0.01% 787
2024
Q4
$265K Buy
5,553
+2,145
+63% +$110K ﹤0.01% 990
2024
Q3
$195K Buy
3,408
+310
+10% +$17.8K ﹤0.01% 944
2024
Q2
$162K Buy
3,098
+252
+9% +$11.1K ﹤0.01% 931
2024
Q1
$116K Hold
2,846
﹤0.01% 1051
2023
Q4
$105K Hold
2,846
﹤0.01% 1045
2023
Q3
$109K Buy
+2,846
New +$117K ﹤0.01% 976
2022
Q4
Sell
-13,061
Closed -$516K 1534
2022
Q3
$516K Sell
13,061
-121
-0.9% -$5.35K ﹤0.01% 753
2022
Q2
$580K Buy
13,182
+8,820
+202% +$381K ﹤0.01% 741
2022
Q1
$174K Hold
4,362
﹤0.01% 1073
2021
Q4
$175K Buy
+4,362
New +$163K ﹤0.01% 1091

Other funds holding HALO

KBC Group's HALO Position: Q1 2026 in Review

KBC Group held its Halozyme (HALO) position steady in Q1 2026 at 3,945 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #903.

KBC Group first reported a position in HALO in Q4 2021 and has held it in 15 quarters since. The position peaked at $580K in Q2 2022. 635 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • KBC Group held 3,945 shares of Halozyme worth $255K as of Q1 2026.
  • KBC Group left its Halozyme share count unchanged in Q1 2026.
  • Halozyme made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #903 holding.
  • KBC Group first reported a position in Halozyme in Q4 2021 and has held it in 15 quarters since.
  • KBC Group's Halozyme position peaked at $580K in Q2 2022.
  • 635 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.